Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCCR-NK92 cells in advanced NSCLC
NCT03656705Phase 1Completed
- Sponsor
- Xinxiang Medical University
- Start
- Sep 2018
- Primary completion
- Nov 2020
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Lymphokine-Activated Killer Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CCCR-NK92 cells in non-small cell lung carcinoma (NSCLC), sponsored by Xinxiang Medical University. Primary endpoints: Number of participants with adverse events at 3 months and Objective Response Rate up to 1 year. Started Sep 2018; status: completed.
02
Drugs
CCCR-NK92 cells
03
Conditions
non-small cell lung carcinoma (NSCLC)
Beyond the preview
Go deeper on NCT03656705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03656705.